US4278684A - Non-toxic anthelminthic pour-on composition - Google Patents
Non-toxic anthelminthic pour-on composition Download PDFInfo
- Publication number
- US4278684A US4278684A US06/160,248 US16024880A US4278684A US 4278684 A US4278684 A US 4278684A US 16024880 A US16024880 A US 16024880A US 4278684 A US4278684 A US 4278684A
- Authority
- US
- United States
- Prior art keywords
- pour
- composition according
- amount
- varying
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 239000004540 pour-on Substances 0.000 title claims abstract description 29
- 230000000507 anthelmentic effect Effects 0.000 title claims abstract description 14
- 231100000252 nontoxic Toxicity 0.000 title 1
- 230000003000 nontoxic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 206010061217 Infestation Diseases 0.000 claims abstract description 7
- 150000001735 carboxylic acids Chemical class 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 54
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 42
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 32
- -1 dicarboxylic acid ester Chemical class 0.000 claims description 21
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 11
- 239000006184 cosolvent Substances 0.000 claims description 9
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 3
- 235000011037 adipic acid Nutrition 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 abstract description 45
- 229960001614 levamisole Drugs 0.000 abstract description 45
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000005690 diesters Chemical class 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000887 hydrating effect Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- KRJNCFVSWZOCKK-UHFFFAOYSA-N 6-(4-methylphenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C1N=C2SCCN2C1 KRJNCFVSWZOCKK-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-UHFFFAOYSA-N 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound N1=C2SCCN2CC1C1=CC=CC=C1 HLFSDGLLUJUHTE-UHFFFAOYSA-N 0.000 description 1
- 206010018999 Haemorrhage subcutaneous Diseases 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100001068 severe skin irritation Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
Definitions
- the method of systemically administering drugs by pouring or spraying a composition, comprising the desired drug, onto any part of the skin is generally known in veterinary medicine as the pour-on method.
- Drugs, administered following this method are absorbed by the skin and, after they have penetrated through the skin, they are transmitted systemically within the animal. [see, for example, W. M. Rogoff and P. H. Kohler, J. Econ. Ent., 53, 814-817 (1960) and B. Idson, J. Pharm., Sci., 64, 901-924 (1975)].
- the drug is preferably applied in admixture with an appropriate carrier, which may be any liquid, taking up an adequate amount of the anthelminthic and permitting an adequate resorption of the drug through the skin without damaging the tissues.
- an appropriate carrier may also consist of a mixture of vehicles, the resulting composition being a cream, a suspension or a solution.
- the pour-on method offers distinct advantages. For example, there is no need to hold the animal, sterile precautions are not necessary and especially trained personal is not required.
- the pour-on method has the advantage that each animal receives an exactly defined amount of the desired drug.
- Tetramisole being chemically designated as 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the laevo isomer thereof, levamisole, have been described in U.S. Pat. Nos. 3,274,209, respectively 3,463,786.
- the compounds are powerful anthelminthic agents.
- Structurally, tetramisole is represented by the formula ##
- Anthelminthic pour-on compositions which contain tetramisole, levamisole or an acid-addition salt thereof, have been described in U.S. Pat. Nos. 4,070,476 and 3,980,791. Said compositions have the disadvantage that the carriers, which are the most effective for helping the penetration of the anthelminthic through the skin, are at the same time the most aggressive to the treated skin, resulting in, for example, subcutaneous bleedings, necrosis, hair and skin diseases and, at worst, open wounds. [severe skin irritations, caused by pour-on compositions, are described, e.g., in Veterinar Medizinische sensoryen 1978 (1), 109-112].
- the present invention describes new pour-on compositions for combating helminthic infestations in a non-human animal.
- the subject compositions are less aggressive and, due to their enhanced skin penetration, they are yielding higher plasma levels.
- This invention relates to pour-on compositions for combating helminthic infestations in a non-human animal, which comprise:
- a an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
- one or more optionally substituted aliphatic carboxylic acids having each a pKa-value comprised between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3;
- the pKa-value has the meaning of -logKa, wherein Ka is the dissociation constant of the most acidic function of the molecule at 25° C. in aqueous medium;
- the term "lower alkyl” is meant to include straight and branched hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like; and "alkylene” comprises straight and branched alkylene chains.
- Suitable optionally substituted aliphatic carboxylic acids are, for example, acetic acid, propionic acid, citric acid, lactic acid and the like. It is unexpectedly observed that in the subject compositions the said carboxylic acids act as specific skin penetration promotors.
- compositions according to the present invention are those wherein the molar ratio of the total amount of the aliphatic carboxylic acids and the total amount of the anthelminthics varies between 0.05 and 1, said carboxylic acids having, more preferably, a pKa-value comprised between 4 and 5.5.
- Particularly preferred compositions are those wherein the aliphatic carboxylic acid is acetic acid.
- Diesters of formula (II) wherein X is a lower alkylene radical having from 3 to 10 C-atoms are especially preferred and compositions containing 25 to 60% of such diesters are more especially preferred.
- Particularly preferred diesters of formula (II) are the di(lower alkyl) esters of adipic acid and the most preferred diesters of formula (II) are those wherein both lower alkyl radicals have 3 carbon atoms.
- levamisole is employed as the anthelminthically active agent, and, in the most preferred embodiment the composition contains from 5 to 20 g. levamisole per 100 ml. of the resulting compositions.
- compositions may also contain additives which may facilitate the administration to the skin of the animal and/or which may be helpful for preparing the desired compositions.
- the compositions preferably comprise also from 10 to 60% of an aliphatic hydrocarbon mixture.
- Said aliphatic hydrocarbons which reduce the surface tension of the compositions, prevent at the same time an excessive adhesion of the applied compositions to the hair and facilitate their spreading over the skin, resulting in an enhanced resorption of the anthelminthic by the skin.
- Useful hydrocarbon mixtures have, preferably, a boiling range comprised between 150° C. and 250° C.
- Particularly preferred hydrocarbon mixtures have a boiling range comprised between 170° C. and 230° C.
- dipolar aprotic solvents which act as a specific penetration promotors and skin protectants, may be advantageous.
- Suitable dipolar aprotic solvents are e.g., N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, N-methyl-2-pyrrolidone and the like.
- Preferred compositions contain from 1 to 30% of a suitable hydrating agent. In the particularly preferred compositions said hydrating agent is N-methyl-2-pyrrolidone. The most preferred compositions contain from 5 to 15% of N-methyl-2-pyrrolidone.
- compositions which are homogeneous In order to prepare compositions which are homogeneous, even at relatively low temperatures, it may be appropriate to add a co-solvent such as, for example, alcohols, e.g., 2-propanol and the like.
- a co-solvent such as, for example, alcohols, e.g., 2-propanol and the like.
- Preferred compositions contain from 0 to 10% of a co-solvent and particularly preferred compositions contain from 0 to 5% of a co-solvent.
- the most preferred co-solvent is 2-propanol.
- compositions may also contain other additives such as, for example, substances whose taste deters animals from licking the applied compositions off the animals treated, pigments making it possible to recognize the treated animals and the like.
- compositions are especially characterized by their effectiveness and by their low ratio of irritation.
- the effectiveness of the concerned anthelminthic pour-on compositions can be demonstrated by the amount of levamisole or tetramisole present in the blood plasma of the animal after treatment of said animal with one of the hereinabove described compositions.
- Venous blood samples are taken on a coagulating agent, e.g., heparine and the like, and, subsequently, they are mixed and centrifugated at 3000 rpm for 5 minutes, thus yielding a supernatant plasma.
- a coagulating agent e.g., heparine and the like
- An aqueous solution consisting of 2 ml. of the above described supernatant plasma, 100 ⁇ l. of a 10 ng/ml. solution of an internal standard, preferably ( ⁇ )-2,3,5,6-tetrahydro-6-(4-methylphenyl)imidazo[2,1-b]thiazole hydrochloride, and 0.5 ml. of sodium hydroxide 10 N is extracted with 4 ml. of a hexane/ether (1/1) mixture. The organic layer is separated and extracted with 2 ml. of a 0.1 N sulfuric acid solution.
- an internal standard preferably ( ⁇ )-2,3,5,6-tetrahydro-6-(4-methylphenyl)imidazo[2,1-b]thiazole hydrochloride
- sodium hydroxide 10 N is extracted with 4 ml. of a hexane/ether (1/1) mixture.
- the organic layer is separated and extracted with 2 ml. of a 0.1 N sulfuric acid solution.
- the aqueous layer is separated, washed with a hexane/ether mixture, alkalized with ammonia to pH 9 and extracted with trichloromethane.
- the trichloromethane layer is separated and the solvent is evaporated at 40° C. under a gentle stream of nitrogen.
- the amount of tetramisole and/or levamisole is determined by separating the components which are present in the hereinabove described sample following art-known gas chromatographic techniques and, subsequently, by comparing the peak area of levamisole and/or tetramisole with the peak area of the internal standard.
- the levamisole and/or tetramisole plasma levels can be determined by the formula: ##EQU1## wherein F is the response factor, which may be determined by the formula: ##EQU2## wherein AI, respectively AR, is the peak area of the internal standard, respectively of the reference compound, and wherein CR and CI are the concentration of the reference compound, respectively the internal standard.
- Table 1 shows the concentrations of levamisole in the blood-plasma of cattle, which have received levamisole by pouring on the back of the animal a composition
- a composition comprising:
- Shellsol T is an aliphatic hydrocarbon fraction having a boiling range comprised between 170° C. and 230° C.
- Column 1 shows the average concentration of levamisole in the plasma of 12 cattle 0.5, 1, 2 and 4 hours after administration of 10 mg per kg of body weight and column 2 shows the average concentrations after administering 4 mg per kg of body weight to 4 cattle.
- Table 2 shows the average concentrations of levamisole in the bloodplasma of 3 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
- Table 3 shows the average concentrations of levamisole in the blood-plasma of 2 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
- Table 4 shows the concentration of levamisole in the bloodplasma of a sheep after treatment with 20 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
- composition comprising:
- compositions can be prepared in a conventional manner, e.g., by adding the desired amounts of levamisole and/or tetramisole to a well-stirred mixture consisting of suitable amounts of the optionally substituted aliphatic carboxylic acids, the di(lower alkyl) carboxylic acid esters of formula (II), the co-solvent and the hydrating agents, and, subsequently, diluting the thus obtained mixture with an appropriate aliphatic hydrocarbon fraction.
- compositions are useful for combating helminthic infestations in all non-human animals, said compositions are especially preferred for the treatment of cattle and sheep.
- composition 1 composition 1:
- Composition 2 is a composition of Composition 2:
- composition 3 is a mixture of composition 3:
- composition 4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to non-aggressive pour-on compositions for combating helminthic infestations in a non-human animal, said compositions comprising an anthelminthic amount of tetramisole and/or levamisole, a carboxylic acid and a di(lower alkyl) ester of a dicarboxylic acid.
Description
The method of systemically administering drugs by pouring or spraying a composition, comprising the desired drug, onto any part of the skin is generally known in veterinary medicine as the pour-on method. Drugs, administered following this method, are absorbed by the skin and, after they have penetrated through the skin, they are transmitted systemically within the animal. [see, for example, W. M. Rogoff and P. H. Kohler, J. Econ. Ent., 53, 814-817 (1960) and B. Idson, J. Pharm., Sci., 64, 901-924 (1975)]. In order to facilitate the penetration through the skin the drug is preferably applied in admixture with an appropriate carrier, which may be any liquid, taking up an adequate amount of the anthelminthic and permitting an adequate resorption of the drug through the skin without damaging the tissues. Said carrier may also consist of a mixture of vehicles, the resulting composition being a cream, a suspension or a solution.
In comparison with the parenteral administration methods the pour-on method offers distinct advantages. For example, there is no need to hold the animal, sterile precautions are not necessary and especially trained personal is not required.
In comparison with the oral administration methods, the pour-on method has the advantage that each animal receives an exactly defined amount of the desired drug.
Tetramisole, being chemically designated as 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the laevo isomer thereof, levamisole, have been described in U.S. Pat. Nos. 3,274,209, respectively 3,463,786. The compounds are powerful anthelminthic agents. Structurally, tetramisole is represented by the formula ##STR1##
Anthelminthic pour-on compositions which contain tetramisole, levamisole or an acid-addition salt thereof, have been described in U.S. Pat. Nos. 4,070,476 and 3,980,791. Said compositions have the disadvantage that the carriers, which are the most effective for helping the penetration of the anthelminthic through the skin, are at the same time the most aggressive to the treated skin, resulting in, for example, subcutaneous bleedings, necrosis, hair and skin diseases and, at worst, open wounds. [severe skin irritations, caused by pour-on compositions, are described, e.g., in Veterinar Medizinische Nachrichten 1978 (1), 109-112].
The present invention describes new pour-on compositions for combating helminthic infestations in a non-human animal. In comparison with the art-known compositions the subject compositions are less aggressive and, due to their enhanced skin penetration, they are yielding higher plasma levels.
This invention relates to pour-on compositions for combating helminthic infestations in a non-human animal, which comprise:
a. an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
b. one or more optionally substituted aliphatic carboxylic acids, having each a pKa-value comprised between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3; and
c. an amount, varying from 10 to 70% by volume, of at least one di(lower alkyl) dicarboxylic acid ester of the formula ##STR2## wherein X represents a direct bond or an alkylene radical having from 1 to 12 carbon atoms.
As used in the foregoing and in the following definitions all percentages refer to volumes; the pKa-value has the meaning of -logKa, wherein Ka is the dissociation constant of the most acidic function of the molecule at 25° C. in aqueous medium; the term "lower alkyl" is meant to include straight and branched hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like; and "alkylene" comprises straight and branched alkylene chains.
Suitable optionally substituted aliphatic carboxylic acids are, for example, acetic acid, propionic acid, citric acid, lactic acid and the like. It is unexpectedly observed that in the subject compositions the said carboxylic acids act as specific skin penetration promotors.
Preferred compositions according to the present invention are those wherein the molar ratio of the total amount of the aliphatic carboxylic acids and the total amount of the anthelminthics varies between 0.05 and 1, said carboxylic acids having, more preferably, a pKa-value comprised between 4 and 5.5. Particularly preferred compositions are those wherein the aliphatic carboxylic acid is acetic acid.
Diesters of formula (II) wherein X is a lower alkylene radical having from 3 to 10 C-atoms are especially preferred and compositions containing 25 to 60% of such diesters are more especially preferred. Particularly preferred diesters of formula (II) are the di(lower alkyl) esters of adipic acid and the most preferred diesters of formula (II) are those wherein both lower alkyl radicals have 3 carbon atoms.
Since the anthelminthic activity of tetramisole is exerted essentially by the laevo isomer, in a preferred embodiment levamisole is employed as the anthelminthically active agent, and, in the most preferred embodiment the composition contains from 5 to 20 g. levamisole per 100 ml. of the resulting compositions.
Besides one or more anthelminthic agents, one or more diesters of formula (II) and one or more optionally substituted aliphatic carboxylic acids the compositions may also contain additives which may facilitate the administration to the skin of the animal and/or which may be helpful for preparing the desired compositions.
In order to reduce their viscosity, the compositions preferably comprise also from 10 to 60% of an aliphatic hydrocarbon mixture. Said aliphatic hydrocarbons, which reduce the surface tension of the compositions, prevent at the same time an excessive adhesion of the applied compositions to the hair and facilitate their spreading over the skin, resulting in an enhanced resorption of the anthelminthic by the skin. Useful hydrocarbon mixtures have, preferably, a boiling range comprised between 150° C. and 250° C. Particularly preferred hydrocarbon mixtures have a boiling range comprised between 170° C. and 230° C.
The presence of dipolar aprotic solvents, which act as a specific penetration promotors and skin protectants, may be advantageous. Suitable dipolar aprotic solvents are e.g., N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, N-methyl-2-pyrrolidone and the like. Preferred compositions contain from 1 to 30% of a suitable hydrating agent. In the particularly preferred compositions said hydrating agent is N-methyl-2-pyrrolidone. The most preferred compositions contain from 5 to 15% of N-methyl-2-pyrrolidone.
In order to prepare compositions which are homogeneous, even at relatively low temperatures, it may be appropriate to add a co-solvent such as, for example, alcohols, e.g., 2-propanol and the like. Preferred compositions contain from 0 to 10% of a co-solvent and particularly preferred compositions contain from 0 to 5% of a co-solvent. The most preferred co-solvent is 2-propanol.
The compositions may also contain other additives such as, for example, substances whose taste deters animals from licking the applied compositions off the animals treated, pigments making it possible to recognize the treated animals and the like.
The above described compositions are especially characterized by their effectiveness and by their low ratio of irritation.
The effectiveness of the concerned anthelminthic pour-on compositions can be demonstrated by the amount of levamisole or tetramisole present in the blood plasma of the animal after treatment of said animal with one of the hereinabove described compositions.
1. Sample preparation:
Venous blood samples are taken on a coagulating agent, e.g., heparine and the like, and, subsequently, they are mixed and centrifugated at 3000 rpm for 5 minutes, thus yielding a supernatant plasma.
2. Extraction procedure:
An aqueous solution, consisting of 2 ml. of the above described supernatant plasma, 100 μl. of a 10 ng/ml. solution of an internal standard, preferably (±)-2,3,5,6-tetrahydro-6-(4-methylphenyl)imidazo[2,1-b]thiazole hydrochloride, and 0.5 ml. of sodium hydroxide 10 N is extracted with 4 ml. of a hexane/ether (1/1) mixture. The organic layer is separated and extracted with 2 ml. of a 0.1 N sulfuric acid solution. Subsequently the aqueous layer is separated, washed with a hexane/ether mixture, alkalized with ammonia to pH 9 and extracted with trichloromethane. The trichloromethane layer is separated and the solvent is evaporated at 40° C. under a gentle stream of nitrogen. To the dry extraction sample there are added 50 μl. of pure methanol, thus yielding a sample which is suitable for gas chromatographic analysis.
3. Determination and calculations:
The amount of tetramisole and/or levamisole is determined by separating the components which are present in the hereinabove described sample following art-known gas chromatographic techniques and, subsequently, by comparing the peak area of levamisole and/or tetramisole with the peak area of the internal standard.
The levamisole and/or tetramisole plasma levels can be determined by the formule: ##EQU1## wherein F is the response factor, which may be determined by the formule: ##EQU2## wherein AI, respectively AR, is the peak area of the internal standard, respectively of the reference compound, and wherein CR and CI are the concentration of the reference compound, respectively the internal standard.
The plasma-levels represented in tables 1, 2, 3 and 4 are intended to illustrate and not to limit the scope of the present invention.
Table 1 shows the concentrations of levamisole in the blood-plasma of cattle, which have received levamisole by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid; and
Shellsol T ad 100 ml,
wherein Shellsol T is an aliphatic hydrocarbon fraction having a boiling range comprised between 170° C. and 230° C.
Column 1 shows the average concentration of levamisole in the plasma of 12 cattle 0.5, 1, 2 and 4 hours after administration of 10 mg per kg of body weight and column 2 shows the average concentrations after administering 4 mg per kg of body weight to 4 cattle.
TABLE 1
______________________________________
μg. levamisole/ml blood plasma
time after
administered administered
treatment
dose = 10 mg/kg body
dose = 4 mg/kg body
in hours weight weight
______________________________________
0.5 0.73 0.29
1 1.44 0.48
2 1.14 0.40
4 0.48 0.19
______________________________________
Table 2 shows the average concentrations of levamisole in the bloodplasma of 3 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
0.5 ml. acetic acid (column a) or
3 ml. acetic acid (column b); and
Shellsol T ad 100 ml.
TABLE 2
______________________________________
μg. levamisole/ml blood plasma
time after administered dose = 10 mg/kg body weight
treatment in hours
0.5% acetic acid
3% acetic acid
______________________________________
0.5 0.97 0.74
1 1.83 1.76
2 0.97 1.17
4 0.58 0.50
______________________________________
Table 3 shows the average concentrations of levamisole in the blood-plasma of 2 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. dibutyl sebacic acid ester;
5 ml. 2-propanol;
1 ml.acetic acid; and
Shellsol T ad 100 ml.
TABLE 3
______________________________________
time after μg. levamisole/ml blood plasma
treatment in hours
administered dose = 10 mg/kg body weight
______________________________________
0.5 0.72
1 1.17
2 0.95
4 0.27
______________________________________
Table 4 shows the concentration of levamisole in the bloodplasma of a sheep after treatment with 20 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid; and
Shellsol T ad 100 ml., (column a).
and by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. dibutyl sebacic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid; and
Shellsol T ad 100 ml. (column b).
TABLE 4 ______________________________________ time after μg. levamisole/ml blood plasma treatment administered dose = 20 mg/kg body weight in hours column a column b ______________________________________ 0.5 0.35 0.29 1 0.40 0.30 2 0.79 0.39 4 0.48 1.02 ______________________________________
The hereinabove described compositions can be prepared in a conventional manner, e.g., by adding the desired amounts of levamisole and/or tetramisole to a well-stirred mixture consisting of suitable amounts of the optionally substituted aliphatic carboxylic acids, the di(lower alkyl) carboxylic acid esters of formula (II), the co-solvent and the hydrating agents, and, subsequently, diluting the thus obtained mixture with an appropriate aliphatic hydrocarbon fraction.
Although the hereinabove described compositions are useful for combating helminthic infestations in all non-human animals, said compositions are especially preferred for the treatment of cattle and sheep.
The following examples are intended to illustrate and not to limit the scope of the present invention.
Over a period of 20 minutes, 10 grams of levamisole are added to a well-stirred mixture, consisting of
10 ml. anhydric N-methyl-2-pyrrolidone;
35 ml. diisopropyl adipate;
5 ml. 2-propanol; and
1 ml. acetic acid.
After completion, the whole is diluted to 100 ml. with Shellsol T.
Following the procedure described in Example 1 the following compositions are prepared:
composition 1:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid;
Shellsol T ad 100 ml.
Composition 2:
10 g. levamisole;
10 ml N-methyl-2-pyrrolidone;
35 ml di(2-propyl) adipic acid ester;
5 ml 2-propanol;
0.5 ml acetic acid;
Shellsol T ad 100 ml.
composition 3:
10 g. levamisole;
10 ml N-methyl-2-pyrrolidone;
35 ml di(2-propyl) adipic acid ester;
5 ml 2-propanol;
3 ml acetic acid;
Shellsol T ad 100 ml.
composition 4:
10 g. levamisole;
10 ml N-methyl-2-pyrrolidone;
35 ml dibutyl sebacic acid ester;
5 ml 2-propanol;
1 ml acetic acid;
Shellsol T ad 100 ml.
Claims (19)
1. A pour-on composition for combating helminthic infestations in a non-human animal, comprising:
a. an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
b. one or more aliphatic carboxylic acids, having each a pKa-value between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3; and
c. an amount, varying from 10 to 70% by volume, of at least one di(lower alkyl) dicarboxylic acid ester of the formula ##STR3## wherein X represents a direct bond or an alkylene radical having from 1 to 12 carbon atoms.
2. A pour-on composition according to claim 1, containing additionally from 1 to 30% of a dipolar aprotic solvent.
3. A pour-on composition according to claim 2, containing additionally from 10 to 60% of an aliphatic hydrocarbon fraction having a boiling range between 150° C. and 250° C.
4. A pour-on composition according to claim 3, wherein the aliphatic hydrocarbon fraction has a boiling range between 170° C. and 230° C.
5. A pour-on composition according to claim 4, wherein the dipolar aprotic solvent is N-methyl-2-pyrrolidone.
6. A pour-on composition for combating helminthic infestations in a non-human animal comprising:
a. an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
b. one or more aliphatic carboxylic acids, having each a pKa-value comprised between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3;
c. an amount, varying from 10 to 70% by volume, of the at least one di(lower alkyl) dicarboxylic acid ester of the formula ##STR4## wherein X represents a direct bond or an alkylene radical having from 1 to 12 carbon atoms;
d. an amount, varying from 5 to 15% of N-methyl-2-pyrrolidone; and
e. an amount, varying from 10 to 60% of an aliphatic hydrocarbon fraction, having a boiling range between 170° C. and 230° C.
7. A pour-on composition according to claim 6, wherein X in the di(lower alkyl) dicarboxylic acid ester of formula (II) represents an alkylene radical having from 3 to 10 carbon atoms.
8. A pour-on composition according to claim 7, wherein the amount of di(lower alkyl) dicarboxylic acid ester of formula (II) varies between 25 and 60%.
9. A pour-on composition according to claim 8, wherein the di(lower alkyl) dicarboxylic acid ester of formula (II) is a di(lower alkyl) adipic acid ester.
10. A pour-on composition according to claim 9, wherein both lower alkyl radicals within the di(lower alkyl)adipic acid ester have 3 carbon atoms.
11. A pour-on composition according to claim 10, comprising additionally from 0 to 15% of a co-solvent.
12. A pour-on composition according to claim 10, comprising additionally from 0 to 5% of a co-solvent.
13. A pour-on composition according to claim 12, wherein the co-solvent is an alcohol.
14. A pour-on composition according to claim 13, wherein the co-solvent is 2-propanol.
15. A pour-on composition according to claim 14, wherein the ratio of the total amount of aliphatic carboxylic acids to the total amount of the anthelminthics varies between 0.05 and 1.
16. A pour-on composition according to claim 15, wherein the aliphatic carboxylic acids have pKa-values between 4 and 5.5.
17. A pour-on composition according to claim 16, wherein the aliphatic carboxylic acid is acetic acid.
18. A pour-on composition according to claim 17, wherein the anthelminthic is l-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole.
19. A pour-on composition for combating helminthic infestations in a non-human animal comprising:
a. from 5 to 20 g. l-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole per 100 ml of the resulting composition;
b. acetic acid, the molar ratio of the amount of acetic acid to the amount of l-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole varying between 0.05 and 1;
c. an amount, varying from 25 to 60% by volume, of di(1-propyl)adipic acid ester and/or di(2-propyl)adipic acid ester;
d. an amount, varying from 5 to 15%, of N-methyl-2-pyrrolidone;
e. an amount, varying from 10 to 60%, of an aliphatic hydrocarbon fraction, having a boiling range between 170° C. and 230° C.; and
f. an amount, varying from 0 to 5% of 2-propanol.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/160,248 US4278684A (en) | 1980-06-17 | 1980-06-17 | Non-toxic anthelminthic pour-on composition |
| CA000377575A CA1157770A (en) | 1980-06-17 | 1981-05-14 | Non-aggressive anthelminthic pour-on composition |
| NZ197293A NZ197293A (en) | 1980-06-17 | 1981-06-03 | Pour-on anthelmintic compositions containing tetramisole and/or levamisole |
| AU71322/81A AU545531B2 (en) | 1980-06-17 | 1981-06-04 | A non-toxic anthelmintic pour-on composition |
| EP81302684A EP0042290B1 (en) | 1980-06-17 | 1981-06-16 | A non-toxic anthelminthic pour-on composition |
| ZA814059A ZA814059B (en) | 1980-06-17 | 1981-06-16 | A non-toxic anthelminthic pour-on composition |
| DE8181302684T DE3172322D1 (en) | 1980-06-17 | 1981-06-16 | A non-toxic anthelminthic pour-on composition |
| IE1335/81A IE51329B1 (en) | 1980-06-17 | 1981-06-16 | A non-toxic anthelminthic pour-on composition |
| AT81302684T ATE15597T1 (en) | 1980-06-17 | 1981-06-16 | NON-TOXIC ANTHELMINTHIC COMPOSITION FOR TOPICAL USE. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/160,248 US4278684A (en) | 1980-06-17 | 1980-06-17 | Non-toxic anthelminthic pour-on composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4278684A true US4278684A (en) | 1981-07-14 |
Family
ID=22576132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/160,248 Expired - Lifetime US4278684A (en) | 1980-06-17 | 1980-06-17 | Non-toxic anthelminthic pour-on composition |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4278684A (en) |
| EP (1) | EP0042290B1 (en) |
| AT (1) | ATE15597T1 (en) |
| AU (1) | AU545531B2 (en) |
| CA (1) | CA1157770A (en) |
| DE (1) | DE3172322D1 (en) |
| IE (1) | IE51329B1 (en) |
| NZ (1) | NZ197293A (en) |
| ZA (1) | ZA814059B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2517205A1 (en) * | 1981-11-27 | 1983-06-03 | Ici Australia Ltd | TETRAMISOLE COMPOSITION FOR TOPICAL APPLICATION TO ANIMALS |
| FR2517207A1 (en) * | 1981-11-27 | 1983-06-03 | Ici Australia Ltd | TOPICAL PARASITICIDE COMPOSITIONS BASED ON LEVAMISOLE AND CYHALOTHRIN |
| WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
| US8512770B2 (en) | 2010-08-04 | 2013-08-20 | Dominion Resources Unlimited, Llc | Skin penetration composition |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1611383A (en) * | 1982-07-02 | 1984-01-05 | Robert Young & Company Limited | Pesticidal formulation with cypermethrin |
| AU2314184A (en) * | 1983-01-10 | 1984-07-12 | Robert Young & Company Limited | Endoparasiticidal composition containing levamisole |
| GB8327761D0 (en) * | 1983-10-17 | 1983-11-16 | Janssen Pharmaceutica Nv | Parasiticidal formulations |
| JPH0747535B2 (en) * | 1985-11-26 | 1995-05-24 | 日東電工株式会社 | Anti-inflammatory analgesic patch |
| AU618517B2 (en) * | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
| AU2002314847A1 (en) | 2001-05-31 | 2002-12-09 | Upsher-Smith Laboratories, Inc. | Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617653B1 (en) * | 1967-09-08 | 1970-06-18 | Meiji Seika Kaisha | Indomethacin preparation for external use |
| IE38848B1 (en) * | 1973-02-23 | 1978-06-07 | Fisons Ltd | Anthelmintic method and composition |
| NL180633C (en) * | 1973-06-22 | 1900-01-01 | Bayer Ag | PROCESS FOR PREPARING AN ANTHELMINTIC EFFECTIVE VETERINARY Pour-on Preparation. |
| US4018932A (en) * | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
| DE2614841A1 (en) * | 1976-04-06 | 1977-10-20 | Bayer Ag | NEW POUR-ON FORMULATIONS FROM ANTHELMINTIKA |
-
1980
- 1980-06-17 US US06/160,248 patent/US4278684A/en not_active Expired - Lifetime
-
1981
- 1981-05-14 CA CA000377575A patent/CA1157770A/en not_active Expired
- 1981-06-03 NZ NZ197293A patent/NZ197293A/en unknown
- 1981-06-04 AU AU71322/81A patent/AU545531B2/en not_active Ceased
- 1981-06-16 DE DE8181302684T patent/DE3172322D1/en not_active Expired
- 1981-06-16 AT AT81302684T patent/ATE15597T1/en not_active IP Right Cessation
- 1981-06-16 EP EP81302684A patent/EP0042290B1/en not_active Expired
- 1981-06-16 IE IE1335/81A patent/IE51329B1/en not_active IP Right Cessation
- 1981-06-16 ZA ZA814059A patent/ZA814059B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Andrews et al., Chem. Abst. vol. 88, (1978), p. 65976j. * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2517205A1 (en) * | 1981-11-27 | 1983-06-03 | Ici Australia Ltd | TETRAMISOLE COMPOSITION FOR TOPICAL APPLICATION TO ANIMALS |
| FR2517207A1 (en) * | 1981-11-27 | 1983-06-03 | Ici Australia Ltd | TOPICAL PARASITICIDE COMPOSITIONS BASED ON LEVAMISOLE AND CYHALOTHRIN |
| DE3244166A1 (en) * | 1981-11-27 | 1983-06-09 | ICI Australia Ltd., 3001 Melbourne, Victoria | PUSH-ON COMPOSITION FOR COMBATING ECTO AND ENDOPARASITES |
| WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
| US8512770B2 (en) | 2010-08-04 | 2013-08-20 | Dominion Resources Unlimited, Llc | Skin penetration composition |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7132281A (en) | 1981-12-24 |
| AU545531B2 (en) | 1985-07-18 |
| CA1157770A (en) | 1983-11-29 |
| ZA814059B (en) | 1983-01-26 |
| ATE15597T1 (en) | 1985-10-15 |
| EP0042290A3 (en) | 1982-09-22 |
| EP0042290A2 (en) | 1981-12-23 |
| DE3172322D1 (en) | 1985-10-24 |
| IE811335L (en) | 1981-12-17 |
| NZ197293A (en) | 1983-05-31 |
| EP0042290B1 (en) | 1985-09-18 |
| IE51329B1 (en) | 1986-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2090422C (en) | Pharmaceutical composition of florfenicol | |
| EP0098743B1 (en) | Phenyl alpha-acyloxyacetamide derivates and their therapeutic use | |
| US4278684A (en) | Non-toxic anthelminthic pour-on composition | |
| CA1161362A (en) | Pharmaceutical compositions containing a corticosteroid substance | |
| US4100297A (en) | Novel anti-acarid methods | |
| SK17452000A3 (en) | COMPOSITIONS COMPRISING ORGANIC MONO- OR DINITRATE FOR TREATINGì (54) IMPOTENCE | |
| US4039664A (en) | Topical griseofulvin composition and method | |
| EP0137627A2 (en) | Pour-on formulation for the control of parasites | |
| KR100529660B1 (en) | Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases | |
| US4439439A (en) | Non-irritating tetramisole- or levamisole pour-on conpositions | |
| EP0061208A1 (en) | Insecticidal control of ectoparasites | |
| EP0294914A2 (en) | Nedocromil for the treatment of dermatological disorders | |
| US4395407A (en) | Parasiticidal pour-on compositions | |
| JP2002504914A (en) | Diclofenac solution prescribed for topical administration | |
| SU1697670A1 (en) | Composition for control of ectoparasites of diseased (psoroptosis, sarcoptosis) farm animals and poultry | |
| CA1252039A (en) | Aqueous non-aggressive anthelmintic pour-on formulations | |
| JPS63238018A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DER VEKEN GUIDO J. L.;DOCKX JOZEF C. J.;REEL/FRAME:003792/0048 Effective date: 19800617 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |